0JDI Stock Chart & Stats
$60.19
-$1.36(-2.43%)
At close: 4:00 PM EDT
$60.19
-$1.36(-2.43%)
Day’s Range― - ―
52-Week Range$43.01 - $86.74
Previous CloseN/A
Volume271.00
Average Volume (3M)2.66K
Market Cap
$7.63B
Enterprise Value$13.25K
Total Cash (Recent Filing)$2.05B
Total Debt (Recent Filing)$2.42B
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Nov 04, 2026EPS Estimate
-1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.46
Shares Outstanding166,184,330
10 Day Avg. Volume3,983
30 Day Avg. Volume2,657
Financial Highlights & Ratios
PEG Ratio1.53
Price to Book (P/B)25.88
Price to Sales (P/S)13.41
P/FCF Ratio-39.55
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$84.00Price Target Upside39.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)-3.6
Revenue Forecast (FY)$921.22M
Bulls Say, Bears Say
Bulls Say
Commercial Launch ExpansionFDA approvals for ZANVASTRO and TRYNGOLZA broaden Ionis’s commercial base beyond partnered economics and establish independent launch capabilities. Their differentiated indications and patient-support infrastructure can create durable product revenue while strengthening the company’s position in RNA-targeted medicines.
RNA Platform And Pipeline ValidationThe positive Phase 3 FUSION result validates Ionis’s antisense approach in a genetically defined neurological disease and may support an expedited regulatory path. Success in this program could add milestone and royalty economics while reinforcing the platform’s ability to generate disease-modifying candidates.
Revenue Growth And Cash RunwayUnderlying first-half revenue growth and a $2.1 billion cash position provide resources to fund commercialization and pipeline development over the next several quarters. Reiterated guidance and management’s 2028 cash-flow breakeven target also indicate a defined, though demanding, path toward greater financial self-sufficiency.
Bears Say
Persistent Cash Burn And LossesContinued operating and free-cash-flow losses mean Ionis is not currently funding its business internally, despite strong gross margins. The projected 2026 operating loss could consume cash needed for launches and research, increasing dependence on existing reserves or future external funding.
Elevated Leverage And Thin EquityDebt-to-equity above 4x and a relatively thin equity base reduce financial flexibility while losses continue. This capital structure can constrain investment choices, make future financing more consequential, and leave less balance-sheet capacity to absorb delays in launches, milestones, or clinical programs.
Partnered Clinical Outcome RiskThe pelacarsen failure shows that important partnered programs can produce major clinical setbacks even when the drug substantially lowers its biological target. Such outcomes can reduce future milestone and royalty potential and make the company’s medium-term profitability roadmap more dependent on other programs.
Ionis Pharmaceuticals News
0JDI FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest share price was $43.01 and its highest was $86.74 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Ionis Pharmaceuticals’s market cap is $7.63B.
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is Nov 04, 2026 which is in 34 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Jul 29, 2026. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$1.089 by $0.399.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -1.21.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 166,184,330 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -$0.69 in its last earnings report, beating expectations of -$1.089. Following the earnings report the stock price went up 0.555%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0JDI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ionis Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$84.00 (39.56% Upside)
$84.00 (39.56% Upside)
Blogger Sentiment
Bullish
GB:0JDI Sentiment 80%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.74%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.31%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ionis Pharmaceuticals
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
0JDI Company Deck
0JDI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong execution across approvals, launches and financials: a landmark approval and early commercial uptake for TRYNGOLZA, accelerating DAWNZERA adoption, solid revenue growth (Q2 revenue $268M, H1 $514M; Q2 commercial revenue $119M up 15% YoY) and a healthy cash position ($2.1B). The company reiterated 2026 guidance and a path to cash-flow breakeven in 2028 while advancing a robust pipeline with multiple near-term catalysts (Zilganersen PDUFA Sept 22, Bepirovirsen PDUFA Oct 26, Pelacarsen readout). Key challenges include the negative CARDIO-TTRansform outcome for Eplontersen, short-term reimbursement frictions (medical exceptions, ICD-10 coding), the Q2 impact from an intentional TRYNGOLZA price reduction, and dependence on partner trial readouts that could affect medium-term profitability. Overall, positives — approvals, launch momentum, strong revenue growth and cash runway — meaningfully outweigh the headwinds described.View all GB:0JDI earnings summaries0JDI Revenue Breakdown
60.82% R&D
39.18% Commercial
0JDI Stock 12 Month Forecast
Average Price Target
$84.00
▲(39.56% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Ascendis Pharma
―
BridgeBio Pharma
―
Revolution Medicines
―
Roivant Sciences
―